[Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].
OBJECTIVE
Drug treatment of cystic fibrosis (CF) is associated with significant costs. To help ensure sustainable care, this study assesses the costs associated with outpatient treatment of adult CF patients in Germany. It identifies main cost drivers, evaluates the potential for cost savings from "aut idem" substitution and presents a projection of lifelong medication costs.


METHODS
The analysis is based on a complete set of prescriptions for adult CF patients from the outpatient clinic of the university hospital of Frankfurt am Main during 2007 (n = 124 patients). Annual treatment costs were calculated on the basis of the "Rote Liste", while the potential for cost savings from "aut idem" drug substitution was obtained through ABDATA Pharma Data Service.


RESULTS
The annual outpatient drug costs for an adult patient with CF averages € 17,219 (n = 124), which increases to € 21,782 if i.v. therapies are included. With an average life expectancy at birth of 39.7 years, total lifetime drug treatment costs amount to € 824,159 (reference year 2007, inflation rate 2.7%, 3% discount rate). "Aut idem" substitution with cheaper drugs could reduce pharmaceutical expenditures by 4.1%.


CONCLUSIONS
Our results confirm the costly nature of drug treatment for CF patients, both on an annual and in particular on a lifelong basis. At the same time, the potential for cost savings through "aut idem" substitution with cheaper drugs remains limited. The added transparency around a small set of costdriving drugs, which is offered in this study, represents a solid contribution to assess treatment choices and financing options to help secure adequate yet sustainable care for CF patients.
Erwachsenen-Mukoviszidoseambulanz, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany. Christoph.Baltin@hhl.de
Christoph T
CT
Baltin
Christina
C
Smaczny
Thomas O
TO
Wagner
D000328:Adult; D000553:Ambulatory Care / Q000191:economics*; D017046:Cost Savings / Q000706:statistics & numerical data; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000191:economics*; D016527:Drug Costs / Q000706:statistics & numerical data*; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D005858:Germany; D005102:Health Expenditures / Q000706:statistics & numerical data; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008134:Long-Term Care / Q000191:economics; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D012189:Retrospective Studies; D055815:Young Adult
D016568:Drugs, Generic
Pediatrics. 1999 Jun;103(6):e72
10353969
Appl Health Econ Health Policy. 2010;8(2):111-8
20175589
Pediatrics. 1997 Aug;100(2 Pt 1):197-204
9240799
Int J Health Care Finance Econ. 2010 Sep;10(3):257-73
20495866
J Cyst Fibros. 2008 Sep;7(5):403-8
18358793
Pharmacoeconomics. 2006;24(11):1087-99
17067194
Pharmacotherapy. 1999 Oct;19(10):1159-66
10512065
Pharmacoeconomics. 2006;24(10):999-1009
17002482
Value Health. 2009 Jun;12(4):409-18
19900249
Aust N Z J Obstet Gynaecol. 2010 Feb;50(1):51-9
20218998
Health Serv Res. 2002 Dec;37(6):1625-42
12546289
Lancet. 2009 Feb 7;373(9662):462
19200917
Thorax. 1998 Jan;53(1):3-4
9577514
Int J Technol Assess Health Care. 2006 Fall;22(4):525-31
16984688
Gesundheitswesen. 2009 Jan;71(1):19-23
19173145
J Cyst Fibros. 2005 Mar;4(1):7-26
15752677
Pharmacoeconomics. 2003;21(14):1001-24
13129414
J Pediatr. 1993 Jan;122(1):1-9
8419592
Thorax. 1992 Sep;47(9):684-9
1440461
Health Econ. 2002 Jun;11(4):285-99
12007162
Eur Respir J. 1996 Nov;9(11):2215-9
8947062
J Palliat Med. 2006 Aug;9(4):884-93
16910803
J Cyst Fibros. 2003 Jun;2(2):84-90
15463855
Med Klin (Munich). 2009 Jul 15;104(7):529-35
19618138
Thorax. 1996 Mar;51(3):298-301
8779135
Curr Med Res Opin. 2007 Apr;23(4):671-82
17407623
Health Econ. 2001 Oct;10(7):601-15
11747044
Pneumonol Alergol Pol. 2004;72(9-10):415-9
16021997
Eur Respir J. 2007 Mar;29(3):522-6
17182652